Incidence of Severe Infections and Infection-Related Mortality during the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study

Arthritis and Rheumatology

Volumn 68, Issue 6, 2016, Pages 1477-1482

  Schmidt, J ^a   Smail, A ^a   Roche, B ^b   Gay, P ^b   Salle, V ^a   Pellet, H ^a   Duhaut, P ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Filieris Medical Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GLIBENCLAMIDE;

AGED; ARTICLE; CAUSE OF DEATH; CLINICAL ASSESSMENT; COHORT ANALYSIS; COLITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ENDOCARDITIS; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MORTALITY RATE; MULTICENTER STUDY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RELAPSE; SEPTIC SHOCK; SKIN INFECTION; TIME TO TREATMENT; TREATMENT DURATION; TUBERCULOSIS; CLINICAL TRIAL; COMPLICATION; MORTALITY; SEVERITY OF ILLNESS INDEX;

AGED; COHORT STUDIES; FEMALE; GIANT CELL ARTERITIS; HUMANS; INCIDENCE; INFECTION; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84971300809     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39596     Document Type: Article

References (21)

1. Salvarani C, Cantini F, Hunder GG., Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-45.
2. Salvarani C, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE., Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004; 51: 264-8.
3. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG., Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49: 703-8.
4. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B., Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-14.
5. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al., Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621-30.
6. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al., for the International Network for the Study of Systemic Vasculitides (INSSYS). A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309-18.
7. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al., A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19: 495-501.
8. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al., The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.
9. Nesher G, Sonnenblick M, Friedlander Y., Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994; 21: 1283-6.
10. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P., Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001; 30: 249-56.
11. Chatelain D, Duhaut P, Schmidt J, Loire R, Bosshard S, Guernou M, et al., Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis 2009; 68: 84-8.
12. Carmona L., Quantifying risks: the case between glucocorticoids and tuberculosis [editorial]. Arthritis Rheum 2006; 55: 1-2.
13. Jick SS, Lieberman ES, Rahman MU, Choi HK., Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55: 19-26.
14. Richeldi L, Losi M, D'Amico R, Luppi M, Ferrari A, Mussini C, et al., Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009; 136: 198-204.
15. Lionakis MS, Kontoyiannis DP., Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828-38.
16. Kloehn S, Arendt T, Reinecke-Luthge A, Klomp HJ, Monig H., Cushing syndrome with life-threatening infectious complications. Dtsch Med Wochenschr 1997; 122: 1547-52. In German.
17. Baschant U, Tuckermann J., The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol 2010; 120: 69-75.
18. Gonzalez-Gay MA, Blanco R, Abraira V, Garcia-Porrua C, Ibanez D, Garcia-Pais MJ, et al., Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality [published erratum appears in J Rheumatol 1998;25:193]. J Rheumatol 1997; 24: 2171-6.
19. Matteson EL, Gold KN, Bloch DA, Hunder GG., Long-term survival of patients with giant cell arteritis in the American College of Rheumatology Giant Cell Arteritis Classification Criteria cohort. Am J Med 1996; 100: 193-6.
20. Bisgard C, Sloth H, Keiding N, Juel K., Excess mortality in giant cell arteritis. J Intern Med 1991; 230: 119-23.
21. Graham E, Holland A, Avery A, Russell RW., Prognosis in giant-cell arteritis. Br Med J (Clin Res Ed) 1981; 282: 269-71.